ISRCTN11978947已完成2 期
Interferon alpha in combination with thalidomide in the treatment of metastatic renal cell carcinoma - a randomised phase II study
K Co-ordinating Committee for Cancer Research (UKCCCR)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Measurable progressive disease (greater than 1 cm non-irradiated marker lesions)
- •2. Calculated creatinine clearance greater than 60 ml/min or ethylene diamine tetra-acetic acid (EDTA) clearance greater than 40 ml/min
- •3. Normal bilirubin
- •4. Liver enzymes less than 5 x upper limit of normal range
排除标准
- •Not provided at time of registration
研究者
相似试验
招募中
不适用
Combination therapy of interferon-alpha and interleukin-2 for patients with metastatic renal cell carcinoma after failure of targeted therapy because of adverse eventsJPRN-UMIN000017717Department of Urology, The University of Tokyo Hospital30
Unknown
2 期
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00027664Cancer Research UK90
进行中（未招募）
不适用
Treatment with leucocytic interferon-alpha more ribavirine towards peg-interferon to reduced doses more ribavirine in patients affections from positive chronic hepatitis HCV that in course of arranged therapy demand the reduction of the peghilato dosage of interferon. - NDEUCTR2005-005161-11-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI200
已完成
不适用
Combination therapy using pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection 3 to 120 months after liver transplantatioHepatitis C reinfection after liver transplantationInfections and InfestationsChronic viral hepatitisISRCTN51477478Hannover Medical School (Medizinische Hochschule Hannover) (Germany)75
已完成
2 期
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular CarcinomaLiverCancerNCT00250796University of New Mexico12